Frontotemporal Disorders Treatment Market

Market Insights on Frontotemporal Disorders Treatment covering sales outlook, demand forecast & up-to-date key trends

Frontotemporal Disorders Treatment Market by Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants), by Treatment (Behavioral Symptoms Management, Psychological Symptoms Management) & Region for 2022-2028

Request Sample Talk to Analyst

Frontotemporal Disorders Treatment Market Overview

[213 Pages Report] The global Frontotemporal Disorders Treatment Market value at around US$ 343.8 Mn in 2022, registering Y-o-Y growth of 4.4%. The market is projected to increase at a CAGR of 4.6% and reach a valuation of US$ 451.4 Mn by 2028.

Frontotemporal Disorders Treatment Market Size (2022)	US$ 343.8 Mn
Sales Forecast (2028)	US$ 451.4 Mn
Global Market Growth Rate (2022 to 2028)	4.6% CAGR
Share of Top 5 Frontotemporal Disorders Treatment System Providers	50%

Currently, frontotemporal disorders treatment holds a share of 4.4% of the global neurological disorder treatment market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars	Details
H1, 2021	4.69%
H1, 2022 Projected	4.64%
H1, 2022 Outlook	4.44%
BPS Change - H1, 2022 (O) – H1, 2022 (P)	(-) 20 ↓
BPS Change – H1, 2022 (O) – H1, 2021	(-) 25 ↓

As per the FMI analysis, H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 20 BPS. However, In H1-2022, the market growth rate of frontotemporal disorders treatment is expected to fall by 25 basis point share (BPS).

The decline in the BPS values observed was attributed the fact that there exist no current disease-modifying drugs approved by the regulatory bodies for the treatment of frontotemporal disorders. With growing changes in lifestyle, and the growing global burden of disease in ageing population, the market faced a heavy demand over the last few decades. With a large gap in the demand and supply, the market likely observed this decline in the BPS values.

Conversely, with advancements in behavioural therapy approaches, the management of symptomatic concerns regarding frontotemporal disorders will provide insights into the growth of the overall market during the forecast years.

The market is highly influenced by patient pool, treatment adoption rate, target population group demography, and disease prevalence, under the impact of macro and industry factors.

Frontotemporal Disorders Treatment Demand Analysis (2013-2021) Compared to Market Forecasts (2022-2028)

“Growing Prevalence of Dementia Expected to Propel Demand for Frontotemporal Disorders Treatment Drugs”

During the historical period of 2013 to 2021, the frontotemporal disorders treatment market expanded at a CAGR of 4.4%.

Frontotemporal disorders are a bunch of rare disorders that include shrinkage of a particular portion of the brain that controls personality, language, and behavior. The condition arises due to the degeneration of frontotemporal cells, which is called frontotemporal lobar degeneration (FTLD).

The typical age range for the onset of frontotemporal dementia is 40 to 60 years; however, it can start after 60 years of age, and the maximum life expectancy after diagnosis is 8–10 years.

With severe dearth of frontotemporal disorders treatment drugs for the reliable treatment of frontotemporal disorders, treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts to date, the condition continues to attract research interests worldwide.

Frontotemporal Disorders Treatment Market Download Report Brochure

Available frontotemporal disorders treatment drugs and other means of frontotemporal disorders treatment do not stop or even decelerate frontotemporal disorders progression, which further remains a key driving force for growing demand for frontotemporal disorders treatment. Expanding incentives for orphan drug development is identified as a prominent factor pushing revenue growth of the frontotemporal disorders treatment industry.

Considering the aforementioned factors, the global frontotemporal disorders treatment market is anticipated to rise at 4.6% CAGR across the 2022 to 2028 time frame.

What are the Prominent Driving Factors for Frontotemporal Disorders Treatment?

“Increasing FTD Drug Development Grants & Funding by Non-Profit Organizations Driving Market Growth”

Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting FTD drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal disorders treatment drugs.

These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop FTD and other rare neurological disease progressions.

Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to the high prevalence of neurological disease among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors are Restraining Demand for Frontotemporal Disorders Treatment?

“Misdiagnosis and Lack of Awareness Limiting Adoption of Neurological Conditions Treatment”

Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thereby limiting the scope of adoption of neurological conditions treatment.

Though clinical trials have resulted in many interventions other than medication, consistently high rate of clinical trial failures is a significant factor that is influencing the growth prospects of neurological conditions treatment.

Which is the Dominant Regional Market for Frontotemporal Disorders Treatment?

“Ongoing Clinical Trials for Frontotemporal Lobar Degeneration (FTLD) to Boost Market Expansion in Western Europe”

Western Europe is expected to contribute 30.5% share in the global frontotemporal disorders treatment market in 2022.

While rapidly growing FTD prevalence and expanding ongoing clinical trials platforms are providing a collective push to the frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence owing to increasing sophistication of the healthcare sector and gradually surging awareness about frontotemporal lobar degeneration (FTLD).

Country-wise Analysis

What Potential Does the U.S. Frontotemporal Disorders Treatment Market Hold?

“Orphan Drug Development Incentives by FDA to Push the Market Forward”

Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.

Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.

Presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool is expected to fuel market growth in the U.S.

How is the Market for Frontotemporal Disorders Treatment Faring in China?

“Higher Prevalence of Frontotemporal Disorders in Older Age Group to Fuel Market Expansion”

China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.

The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.

Category-wise Insights

Which Disease Indication Will Hold Maximum Sway?

“Initiatives by Mental Treatment Centers for Frontotemporal Dementia Patients to Boost Market Growth”

Based on disease indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture clinical research interests.

Rapid development of new frontotemporal dementia therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.

Furthermore, frontotemporal dementia therapeutics are anticipated to witness major contributions from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.

Which Distribution Channel is Driving Demand for Frontotemporal Disorders Treatment Products?

“Hospital Pharmacies Most Preferred Due to Easy Availability of Frontotemporal Disorders Treatment Drugs”

Hospital pharmacies are expected to hold the highest market share over the forecast period. Majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

However, there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.

Impact of COVID-19 on Market

The frontotemporal disorders treatment market, like many others, was heavily damaged by the COVID-19 pandemic. An increase in infection fear among persons of all ages has resulted from an increasing number of COVID-positive cases that have resulted in mortality and morbidity all across the world.

In addition, limits on travel and movement, social distance conventions, and hospital beds reserved for COVID patients reduced clinical and hospital visits.

However, the emergence of virtual healthcare consultations and remote patient monitoring, as well as an increase in COVID-19 vaccines and lifting of lockdown limitations, will enable the market for frontotemporal disorders treatment devices to quickly recover and grow significantly over the coming years.

Competitive Landscape

In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.

For instance,

AstraZeneca Plc recently inked an agreement with Luye Pharma Group, Ltd. over the licensing and sales of Seroquel and Seroquel XR across China and the U.K, in addition to a few other international markets. The drug is occasionally used to address a set of behavioral problems associated with FTD.

Frontotemporal Disorders Treatment Industry Report Scope

Attribute	Details
Forecast Period	2022-2028
Historical Data Available for	2013-2021
Market Analysis	Value in US$ Mn
Key Regions Covered	North America Latin America Europe East Asia South Asia & Pacific Middle East & Africa (MEA)
Key Countries Covered	U.S. Canada Mexico Brazil Mexico Argentina Germany Italy France U.K Nordic Spain Japan China India Malaysia Thailand Australia GCC Countries South Africa Turkey
Key Market Segments Covered	Drug Class Treatment Disease Indication Distribution Channel Region
Key Companies Profiled	Pfizer Inc. Johnson & Johnson Sanofi S.A. Eli Lilly and Company GlaxoSmithKline Plc. Novartis AG Mylan N.V. Merck & Company, Inc. AstraZeneca plc. Allergen plc
Pricing	Available upon Request

Key Segments of Frontotemporal Disorders Treatment Industry Research

By Drug Class:

Cognitive Enhancers
Antipsychotics
Antidepressants
CNS Stimulants
Others

By Treatment:

Behavioral Symptoms Management
Psychological Symptoms Management

By Disease Indication:

Frontotemporal Dementia
Primary Progressive Aphasia
Movement Disorders

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

By Region:

North America Frontotemporal Disorders Treatment Market
Latin America Frontotemporal Disorders Treatment Market
Europe Frontotemporal Disorders Treatment Market
East Asia Frontotemporal Disorders Treatment Market
South Asia & Pacific Frontotemporal Disorders Treatment Market
Middle East & Africa (MEA) Frontotemporal Disorders Treatment Market

Frequently Asked Questions

How much is the frontotemporal disorders treatment market expected to be worth in 2022?

As of 2022, the global frontotemporal disorders treatment market is expected to reach US$ 343.8 Mn.

Which are the top 5 countries driving demand for frontotemporal disorders treatment?

France, China, Germany, India, and the U.S. are the top 5 countries driving most demand for frontotemporal disorders treatment.

Which are the leading companies manufacturing frontotemporal disorders treatment products?

Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, and GlaxoSmithKline Plc. are leading companies in this market.

What is the future growth rate of the frontotemporal disorders treatment market for the forecast period?

The frontotemporal disorders treatment market is expected to rise at a CAGR of around 4.6% during the period of 2022-2028.

Which region has the largest market for frontotemporal disorders treatment?

Western Europe accounts for 30.5% share of the global frontotemporal disorders treatment market.

Table of Content

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Frontotemporal Disorders Treatment Market Opportunity Analysis

3.1. Macro-Economic Factors

3.2. Opportunity Analysis & Pipeline Assessment

4. Market Background

4.1. Market Dynamics

4.1.1. Drivers

4.1.2. Restraints

4.1.3. Trends

5. Key Inclusions

5.1. Disease Epidemiology

6. North America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

6.1. Introduction

6.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

6.2.1. U.S.

6.2.2. Canada

6.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

6.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

6.4.1. Cognitive Enhancers

6.4.2. Antipsychotics

6.4.3. Antidepressants

6.4.4. CNS Stimulants

6.4.5. Others

6.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

6.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

6.6.1. Behavioral Symptom Management

6.6.2. Psychological Symptoms Management

6.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

6.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

6.8.1. Frontotemporal Dementia

6.8.2. Primary Progressive Aphasia

6.8.3. Movement Disorders

6.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

6.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

6.10.1. Hospital Pharmacies

6.10.2. Retail Pharmacy

6.10.3. Drug Stores

6.10.4. Online Pharmacy

6.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

6.12. Market Attractiveness Analysis

6.12.1. By Country

6.12.2. By Drug Class

6.12.3. By Treatment Type

6.12.4. By Disease Indication

6.12.5. By Distribution Channel

7. Latin America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

7.1. Introduction

7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

7.2.1. Brazil

7.2.2. Mexico

7.2.3. Rest of Latin America

7.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

7.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

7.4.1. Cognitive Enhancers

7.4.2. Antipsychotics

7.4.3. Antidepressants

7.4.4. CNS Stimulants

7.4.5. Others

7.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

7.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

7.6.1. Behavioral Symptom Management

7.6.2. Psychological Symptoms Management

7.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

7.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

7.8.1. Frontotemporal Dementia

7.8.2. Primary Progressive Aphasia

7.8.3. Movement Disorders

7.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

7.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

7.10.1. Hospital Pharmacies

7.10.2. Retail Pharmacy

7.10.3. Drug Stores

7.10.4. Online Pharmacy

7.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

7.12. Market Attractiveness Analysis

7.12.1. By Country

7.12.2. By Drug Class

7.12.3. By Treatment Type

7.12.4. By Disease Indication

7.12.5. By Distribution Channel

8. Western Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

8.1. Introduction

8.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

8.2.1. Germany

8.2.2. U.K

8.2.3. France

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Western Europe

8.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

8.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

8.4.1. Cognitive Enhancers

8.4.2. Antipsychotics

8.4.3. Antidepressants

8.4.4. CNS Stimulants

8.4.5. Others

8.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

8.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

8.6.1. Behavioral Symptom Management

8.6.2. Psychological Symptoms Management

8.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

8.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

8.8.1. Frontotemporal Dementia

8.8.2. Primary Progressive Aphasia

8.8.3. Movement Disorders

8.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

8.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

8.10.1. Hospital Pharmacies

8.10.2. Retail Pharmacy

8.10.3. Drug Stores

8.10.4. Online Pharmacy

8.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

8.12. Market Attractiveness Analysis

8.12.1. By Country

8.12.2. By Drug Class

8.12.3. By Treatment Type

8.12.4. By Disease Indication

8.12.5. By Distribution Channel

9. Eastern Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

9.1. Introduction

9.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

9.2.1. Russia

9.2.2. Poland

9.2.3. Rest of Eastern Europe

9.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

9.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

9.4.1. Cognitive Enhancers

9.4.2. Antipsychotics

9.4.3. Antidepressants

9.4.4. CNS Stimulants

9.4.5. Others

9.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

9.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

9.6.1. Behavioral Symptom Management

9.6.2. Psychological Symptoms Management

9.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

9.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

9.8.1. Frontotemporal Dementia

9.8.2. Primary Progressive Aphasia

9.8.3. Movement Disorders

9.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

9.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

9.10.1. Hospital Pharmacies

9.10.2. Retail Pharmacy

9.10.3. Drug Stores

9.10.4. Online Pharmacy

9.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

9.12. Market Attractiveness Analysis

9.12.1. By Country

9.12.2. By Drug Class

9.12.3. By Treatment Type

9.12.4. By Disease Indication

9.12.5. By Distribution Channel

10. Asia Pacific Excluding Japan (APEJ) Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

10.1. Introduction

10.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

10.2.1. India

10.2.2. China

10.2.3. Australia

10.2.4. ASEAN

10.2.5. Rest of APEJ

10.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

10.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

10.4.1. Cognitive Enhancers

10.4.2. Antipsychotics

10.4.3. Antidepressants

10.4.4. CNS Stimulants

10.4.5. Others

10.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

10.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

10.6.1. Behavioral Symptom Management

10.6.2. Psychological Symptoms Management

10.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

10.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

10.8.1. Frontotemporal Dementia

10.8.2. Primary Progressive Aphasia

10.8.3. Movement Disorders

10.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

10.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

10.10.1. Hospital Pharmacies

10.10.2. Retail Pharmacy

10.10.3. Drug Stores

10.10.4. Online Pharmacy

10.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

10.12. Market Attractiveness Analysis

10.12.1. By Country

10.12.2. By Drug Class

10.12.3. By Treatment Type

10.12.4. By Disease Indication

10.12.5. By Distribution Channel

11. Japan Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

11.1. Introduction

11.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

11.2.1. Cognitive Enhancers

11.2.2. Antipsychotics

11.2.3. Antidepressants

11.2.4. CNS Stimulants

11.2.5. Others

11.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

11.4. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

11.4.1. Behavioral Symptom Management

11.4.2. Psychological Symptoms Management

11.5. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

11.6. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

11.6.1. Frontotemporal Dementia

11.6.2. Primary Progressive Aphasia

11.6.3. Movement Disorders

11.7. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

11.8.1. Hospital Pharmacies

11.8.2. Retail Pharmacy

11.8.3. Drug Stores

11.8.4. Online Pharmacy

11.9. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

11.10. Market Attractiveness Analysis

11.10.1. By Country

11.10.2. By Drug Class

11.10.3. By Treatment Type

11.10.4. By Disease Indication

11.10.5. By Distribution Channel

12. Middle East and Africa Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

12.1. Introduction

12.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021

12.2.1. GCC Countries

12.2.2. South Africa

12.2.3. Rest of MEA

12.3. Market Value (US$ Mn) Forecast By Country, 2022–2028

12.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

12.4.1. Cognitive Enhancers

12.4.2. Antipsychotics

12.4.3. Antidepressants

12.4.4. CNS Stimulants

12.4.5. Others

12.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

12.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021

12.6.1. Behavioral Symptom Management

12.6.2. Psychological Symptoms Management

12.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

12.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021

12.8.1. Frontotemporal Dementia

12.8.2. Primary Progressive Aphasia

12.8.3. Movement Disorders

12.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

12.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

12.10.1. Hospital Pharmacies

12.10.2. Retail Pharmacy

12.10.3. Drug Stores

12.10.4. Online Pharmacy

12.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

12.12. Market Attractiveness Analysis

12.12.1. By Country

12.12.2. By Drug Class

12.12.3. By Treatment Type

12.12.4. By Disease Indication

12.12.5. By Distribution Channel

13. Forecast Factors: Relevance and Impact

14. Driver Restraint Impact Analysis

15. Market Structure Analysis

16. Competition Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Profitability and Gross Margin Analysis By Competition

16.4. Competitors Deep Dive (Company Overview, Footprint, Strategies, Financials, Key Development)

16.4.1. Pfizer Inc.

16.4.2. Johnson & Johnson

16.4.3. Sanofi S.A.

16.4.4. Eli Lilly and Company

16.4.5. GlaxoSmithKline Plc.

16.4.6. GlaxoSmithKline Plc.

16.4.7. Mylan N.V.

16.4.8. Merck & Company, Inc.

16.4.9. AstraZeneca plc.

16.4.10. Allergan Plc.

17. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 By Region

17.1. Introduction / Key Findings

17.2. Historical Market Value (US$ Mn) Analysis By Region

17.2.1. North America

17.2.2. Western Europe

17.2.3. Eastern Europe

17.2.4. Latin America

17.2.5. Asia Pacific Excluding Japan

17.2.6. Japan

17.2.7. Middle East and Africa

17.3. Market Value (US$ Mn) Forecast By Region

17.4. Market Attractiveness Analysis By Region

18. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Drug Class

18.1. Introduction/Key Finding

18.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021

18.2.1. Cognitive Enhancers

18.2.2. Antipsychotics

18.2.3. Antidepressants

18.2.4. CNS Stimulants

18.2.5. Others

18.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028

18.4. Market Attractiveness Analysis By Drug Class

19. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Treatment Type

19.1. Introduction/Key Finding

19.2. Historical Market Value (US$ Mn) Analysis By Treatment Type, 2013-2021

19.2.1. Frontotemporal Dementia

19.2.2. Primary Progressive Aphasia

19.2.3. Movement Disorders

19.3. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028

19.4. Market Attractiveness Analysis By Treatment Type

20. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Disease Indication

20.1. Introduction/Key Finding

20.2. Historical Market Value (US$ Mn) Analysis By Disease Indication, 2013-2021

20.2.1. Frontotemporal Dementia

20.2.2. Primary Progressive Aphasia

20.2.3. Movement Disorders

20.3. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028

20.4. Market Attractiveness Analysis By Disease Indication

21. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Distribution Channel

21.1. Introduction/Key Finding

21.2. Historical Market Value (US$ Mn) Analysis By Distribution Channel, 2013-2021

21.2.1. Hospital Pharmacies

21.2.2. Retail Pharmacy

21.2.3. Drug Stores

21.2.4. Online Pharmacy

21.3. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028

21.4. Market Attractiveness Analysis By Distribution Channel

22. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028

22.1. Market Value Share Analysis By All Segment

22.2. Y-o-Y Growth Analysis By All Segment

22.3. Absolute $ Opportunity

23. Assumptions and Acronyms Used

24. Research Methodology

List of Tables

Table 01: NIH Estimated Funding for Frontotemporal Dementia

Table 02: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021)

Table 03: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021)

Table 04: Non-Profit Organizations Driving FTD Therapeutics Development

Table 05: Non-Profit Organizations Driving FTD Therapeutics Development

Table 06: World Population Aged 65 and Over by Sex: 2015, 2030, and 2050 (Numbers in millions)

Table 07: Prevalence of Frontotemporal Dementia, By Region

Table 08: Prevalence of Frontotemporal Dementia, By Region

Table 09: Prevalence of Primary Progressive Aphasia , By Region

Table 10: Prevalence of Primary Progressive Aphasia , By Region

Table 11: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 12: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 13: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 14: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 15: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 16: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 17: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 18: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 19: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 20: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 21: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 22: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 23: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 24: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 25: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 26: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 27: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 28: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 29: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 30: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 31: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 32: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 33: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 34: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 35: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 36: Japan Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 37: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 38: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 39: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 40: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 41: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 42: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type

Table 43: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 44: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 45: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Region

Table 46: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class

Table 47: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Treatment Type

Table 48: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication

Table 49: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure  1: Global Frontotemporal Disorders Treatment Market Split By Drug Class (2022)

Figure  2: Global Frontotemporal Disorders Treatment Market Split Treatment Type (2022)

Figure  3: Global Frontotemporal Disorders Treatment Market Split By Distribution Channel (2022)

Figure  4: Global Frontotemporal Disorders Treatment Market Split By Disease Indication (2022)

Figure  5: Global Frontotemporal Disorders Treatment Market Split By Region (2022)

Figure  6: Economic Burden of Major Neurological Disease in United States % (2014)

Figure  7: Distribution of Industry Sponsored Clinical Programs for Frontotemporal Disorders Drugs, by Phase

Figure  8: Global Impact of Dementia

Figure  9: Incidence of FTD By Age

Figure  10: Prevalence of Frontotemporal Dementia Across the Globe

Figure  11: Prevalence of Primary Progressive Aphasia (PPA) Across the Globe

Figure  12: North America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  13: North America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  14: U.S. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  15: U.S. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  16: Canada Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  17: Canada Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  18: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country

Figure  19: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  20: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  21: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  22: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  23: Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  24: Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  25: Brazil Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  26: Brazil Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  27: Mexico Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  28: Mexico Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  29: Rest of Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  30: Rest of Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  31: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country

Figure  32: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  33: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  34: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  35: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  36: Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  37: Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  38: Germany Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  39: Germany Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  40: Italy Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  41: Italy Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  42: France Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  43: France Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  44: U.K. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  45: U.K. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  46: Spain Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  47: Spain Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  48: Rest of Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  49: Rest of Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  50: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country

Figure  51: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  52: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  53: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  54: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  55: Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  56: Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  57: Russia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  58: Russia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  59: Poland Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  60: Poland Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  61: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  62: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  63: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country

Figure  64: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  65: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  66: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  67: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  68: APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  69: APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  70: China Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  71: China Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  72: India Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  73: India Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  74: Australia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  75: Australia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  76: ASEAN Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  77: ASEAN Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  78: Rest of APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  79: Rest of APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  80: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country

Figure  81: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  82: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  83: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  84: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  85: Japan Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  86: Japan Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  87: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  88: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  89: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  90: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  91: MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  92: MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  93: GCC Countries Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  94: GCC Countries Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  95: South Africa Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  96: South Afric Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  97: Rest of MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021

Figure  98: Rest of MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure  99: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country

Figure  100: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  101:  MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  102: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  103: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  104: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Region

Figure  105: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class

Figure  106: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type

Figure  107: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication

Figure  108: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel

Figure  109: Global Frontotemporal Disorders Treatment Market Historical Market Value and Y-o-Y, 2013-2022

Figure  110: Global Frontotemporal Disorders Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure  111: Global Frontotemporal Disorders Treatment Market Absolute $ Opportunity, 2013–2028